GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » Price-to-Free-Cash-Flow

Glenmark Pharmaceuticals (BOM:532296) Price-to-Free-Cash-Flow : N/A (As of Oct. 31, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-10-31), Glenmark Pharmaceuticals's share price is ₹1670.90. Glenmark Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was ₹0.00. Hence, Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Glenmark Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 1728.08. The lowest was 0.00. And the median was 16.51.

BOM:532296's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.17
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Glenmark Pharmaceuticals's Free Cash Flow per Share for the three months ended in Jun. 2024 was ₹0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was ₹0.00.

During the past 13 years, Glenmark Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 54.10% per year. The lowest was -66.30% per year. And the median was -9.80% per year.


Glenmark Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Price-to-Free-Cash-Flow Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.61 36.77 39.17 744.00 -

Glenmark Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Glenmark Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1670.90/0
=N/A

Glenmark Pharmaceuticals's Share Price of today is ₹1670.90.
Glenmark Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Glenmark Pharmaceuticals  (BOM:532296) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Glenmark Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals Headlines

No Headlines